CAJ | 학술논문

目的：观察吉非替尼在中晚期非小细胞肺癌的疗效。方法：40例晚期非小细胞肺癌患者口服吉非替尼250mg／d，观察 RR、DCR、PFS、OS 及不良反应发生率。结果：40例患者中，CR 1例，PR 18例，SD 13例，PD 8例，RR 为47．5％，吉非替尼在优势人群中有效率约72％左右；中位有效时间为8～10个月。结论：吉非替尼在 EGFR 基因突变患者中疗效明显，可显著延长生存期，提高生活质量，且安全性高，毒性可耐受。在女性、腺癌、不吸烟人群中疗效更明确，临床获益显著。
목적：관찰길비체니재중만기비소세포폐암적료효。방법：40례만기비소세포폐암환자구복길비체니250mg／d，관찰 RR、DCR、PFS、OS 급불량반응발생솔。결과：40례환자중，CR 1례，PR 18례，SD 13례，PD 8례，RR 위47．5％，길비체니재우세인군중유효솔약72％좌우；중위유효시간위8～10개월。결론：길비체니재 EGFR 기인돌변환자중료효명현，가현저연장생존기，제고생활질량，차안전성고，독성가내수。재녀성、선암、불흡연인군중료효경명학，림상획익현저。
Objective:To observe the efficacy of Gefitinib targeted therapy for advanced non -small cell lung cancer(NSCLC).Methods:Forty patients with advanced NSCLC took orally Gefitinib 250mg everyday.To observe RR,DCR,PFS,OS and adverse effects.Results:In 40 patients,one achieved complete response,eight achieved partial response,thirteen patients achieved stable disease,eight patients were progress disease,effective rate was 47.5%. Advantaged patients effective rate of Gefitinib was 72%.The median effective time were 8 to 10 months.Conclusion:Gefitinib in NSCLC patients of epidermal growth factor receptor mutational status were more effective.It may improve the survival and enhance the quality of life.It is safe and low toxic.